USPTO serial 87286142
VITAFENOL
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- SANDER, DREW M
- Law office
- TMO LAW OFFICE 110 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with VITAFENOL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Drug testing kits comprised of medical diagnostic reagents and assays for testing body fluids; Nutritional meal replacement bars adapted for medical use for individuals undergoing medical treatments; Nutritionally fortified beverages for medical purposes; Nutritionally fortified water for medical purposes; Nutritive substances for micro-organisms for medical use; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for reducing sexual activity; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of worms in pets; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating sunburn; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, antivirals; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, dantrolene sodium for injection; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for chloasma; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products and preparations to prevent swelling in the legs; Albumin dietary supplements; Alginate dietary supplements; Aloe vera preparations for pharmaceutical purposes; Animal feed supplements; Animal feed additive for use as a nutritional supplement for medical purposes; Anti-epileptic pharmaceutical preparations; Antioxidant enriched coffee for medical purposes; Bismuth preparations for pharmaceutical purposes; Calcium supplements; Calcium fortified candy for medical purposes; Casein dietary supplements; Dietary supplements; Dietary supplements for animals; Dietary supplements for controlling cholesterol; Dietary supplements for human consumption; Dietary supplements for pets; Dietary supplements for urinary health; Dietary and nutritional supplements; Dietary and nutritional supplements for endurance sports; Dietary food supplements; Enzyme dietary supplements; Enzyme food supplements; Flaxseed dietary supplements; Flaxseed oil dietary supplements; Food supplements; Food supplements, namely, anti-oxidants; Food supplements, namely, anti-oxidants; Glucose dietary supplements; Health food supplements; Herbal supplements; Herbal supplements for sleeping problems; Homeopathic supplements; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; Lecithin dietary supplements; Linseed dietary supplements; Linseed oil dietary supplements; Liquid herbal supplements; Liquid protein supplements; Liquid vitamin supplements; Medicated supplements for foodstuffs for animals; Medicated supplements for foodstuffs for babies; Mineral supplements; Mineral food supplements; Mineral nutritional supplements; Mineral, vitamin, or nutritionally enhanced water for medical purposes; Natural supplements for treating candida; Natural supplements for treating depression and anxiety; Natural supplements for treating erectile dysfunction; Natural dietary supplements; Natural herbal supplements; Non-medicated additives for animal feed for use as nutritional supplements; Non-medicated additives for animal feed for use as nutritional supplements; Nutritional supplements; Nutritional supplements in capsule form for dogs; Nutritional supplements, namely, carbohydrates in powdered form; Nutritional supplements, namely, probiotic compositions; Nutritionally fortified beverages for medical purposes; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pollen dietary supplements; Potassium preparations for pharmaceutical purposes; Prebiotic supplements; Probiotic supplements; Propolis dietary supplements; Protein supplements; Protein supplements for animals; Protein dietary supplements; Radioactive pharmaceutical preparations for use in vivo diagnostic or therapeutic use; Royal jelly dietary supplements; Soy isoflavone dietary supplements; Soy protein dietary supplements; Vegan liquid protein supplements; Veterinary preparations, namely, antioxidants; Vitamin supplements; Vitamin and mineral supplements; Vitamin enriched chewing gum for medical purposes; Vitamin enriched sparkling water for medical purposes; Vitamin enriched water for medical purposes; Vitamin fortified beverages for medical purposes; Vitamin fortified beverages for medical purposes; Vitamins and dietary food supplements for animals; Weight management supplements; Wheat germ dietary supplements; Whey protein supplements; Yeast dietary supplements | ACTIVE | May 21, 2015 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 3, 2017 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Nov 3, 2017 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Mar 27, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 27, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 27, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 27, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 11, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 3, 2017 | NWAP | NEW APPLICATION ENTERED | — |